TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33977884

Group type: EXPERIMENTAL
Intervention: Syllable-based reading training (24 sessions)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 101
Study: 34011396

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided VPS placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stereotactic navigated VPS placement using optical tracking
Number of subjects: 0
Study: 32631422

Group type: EXPERIMENTAL
Intervention: BruMeChol™ dietary supplement (one capsule two times a day for 12 weeks)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo (one capsule two times a day for 12 weeks)
Number of subjects: 125
Study: 36062966

Group type: EXPERIMENTAL
Intervention: Somapacitan (0.16 mg/kg/wk)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Daily GH (Norditropin; 0.034 mg/kg/d)
Number of subjects: 200
Study: 33403759

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) infusion during OLDH
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 34
Study: 32584168

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Number of subjects: 0
Study: 35726291

Group type: EXPERIMENTAL
Intervention: Somatostatin combined with transnasal ileus catheterization
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 94
Study: 33567191

Group type: EXPERIMENTAL
Intervention: Topical tirbanibulin ointment (1% applied once daily for 5 days)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Vehicle (placebo) ointment
Number of subjects: 702
Study: 32293501

Group type: EXPERIMENTAL
Intervention: Minimally invasive screw fixation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 50
Study: 35469503

Group type: EXPERIMENTAL
Intervention: Propensity Score Stratification (PSS) in a partially randomized preference design (PRPD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 to 10 propensity score strata
Number of subjects: 0
Study: 34930893

Group type: EXPERIMENTAL
Intervention: Gaze-contingent attention training (n=20)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Passive viewing of videos (n=23)
Number of subjects: 43
Study: 35927745

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 104
Study: 32910813

Group type: EXPERIMENTAL
Intervention: Leucine supplementation (LEU; n=8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control leg (CTL)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Leucine supplementation (LEU) and placebo (PLA)
Number of subjects: 16
Study: 35710695

Group type: EXPERIMENTAL
Intervention: Electrodes placed in the anatomical position
Number of subjects: 203

Group type: COMPARATOR
Intervention: Electrodes placed at 5‐cm intervals
Number of subjects: 203
Study: 32580920

Group type: EXPERIMENTAL
Intervention: BOPT (biologically oriented preparation technique)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Horizontal chamfer finishing line (control group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (BOPT and control)
Number of subjects: 40
Study: 32142566

Group type: EXPERIMENTAL
Intervention: Albumin-impregnated bone allograft (BoneAlbumin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bovine xenograft (Bio-Oss)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (empty socket)
Number of subjects: 24
Study: 33887165

Group type: EXPERIMENTAL
Intervention: Acute circuit training (CT) - 12‐15 repetitions; 65‐70% of 1‐repetition maximum; 3 loops
Number of subjects: 29
Study: 35030352

Group type: EXPERIMENTAL
Intervention: Virtual simulation intervention
Number of subjects: 88
Study: 33392915

Group type: EXPERIMENTAL
Intervention: Experimental group (owners informed the walk would be digitally recorded for evaluation)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (owners informed the walk would be digitally recorded for archival purposes)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 32589506

Group type: EXPERIMENTAL
Intervention: Volanesorsen 300 mg SC
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Volanesorsen 300 mg IV
Number of subjects: 52

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 36117306

Group type: EXPERIMENTAL
Intervention: Fear of COVID-19
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mediation effect of depression
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Social distancing
Number of subjects: 300
Study: 35195075

Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilatation combined with submucosal injection of 40 mg prednisolone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional endoscopic balloon dilatation
Number of subjects: 64
Study: 32380660

Group type: EXPERIMENTAL
Intervention: Intravenous iron (1 g ferric carboxymaltose, n = 86)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (10 g iron fumarate, 100 capsules, n = 90)
Number of subjects: 176
Study: 36177443

Group type: EXPERIMENTAL
Intervention: Glibenclamide (1.25 mg, 3 times/day) with standard care
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Glibenclamide (1.25 mg, 3 times/day)
Number of subjects: 200
Study: 34157996

Group type: EXPERIMENTAL
Intervention: Platinum-containing dual-drug chemotherapy combined with Bifico
Number of subjects: 180

Group type: COMPARATOR
Intervention: Platinum-containing dual-drug chemotherapy
Number of subjects: 180
Study: 32091594

Group type: EXPERIMENTAL
Intervention: Single-dose bivalent HPV vaccine
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Two-dose bivalent HPV vaccine
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Three-dose bivalent HPV vaccine
Number of subjects: 112

Group type: COMPARATOR
Intervention: Unvaccinated women
Number of subjects: 112
Study: 35872530

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg twice a day (BD)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Olaparib 200 mg three times a day (TDS)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo BD
Number of subjects: 220
Study: 34023024

Group type: EXPERIMENTAL
Intervention: Preclinical randomized controlled trials (pRCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Animal studies
Number of subjects: 0
Study: 32840297

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure of 70-80 mmHg during cardiopulmonary bypass (CPB)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Mean arterial pressure of 40-50 mmHg during cardiopulmonary bypass (CPB)
Number of subjects: 197
Study: 35429281

Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg subcutaneous every 4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg subcutaneous every 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33813611

Group type: EXPERIMENTAL
Intervention: CBD expectancy condition
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Strong a priori beliefs about CBD
Number of subjects: 43

Group type: COMPARATOR
Intervention: CBD-free hempseed oil
Number of subjects: 43
Study: 32967974

Group type: EXPERIMENTAL
Intervention: PrEP promotion package
Number of subjects: 1538
Study: 36384481

Group type: EXPERIMENTAL
Intervention: Opioid-reduced anesthesia (Group MO) with esketamine and alfentanil
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Opioid-reduced anesthesia (Group LO) with esketamine and alfentanil
Number of subjects: 141

Group type: COMPARATOR
Intervention: Traditional opioid-based anesthesia (Group C) with alfentanil
Number of subjects: 141
Study: 32283944

Group type: EXPERIMENTAL
Intervention: High education level
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: Physician continuity
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: Written action plan
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: Step 2 maintenance treatment
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: Step 3 treatment
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: Asthma/COPD nurse visit (women)
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: Co-morbidities ≥1
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: Self-rated moderate/severe disease
Number of subjects: 1442
Study: 35903029

Group type: EXPERIMENTAL
Intervention: FIFA 11+ Kids program
Number of subjects: 780

Group type: COMPARATOR
Intervention: Usual warm-ups
Number of subjects: 780
Study: 34491349

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Self-adhesive resin cement
Number of subjects: 30
Study: 32269148

Group type: EXPERIMENTAL
Intervention: NeuroPAP
Number of subjects: 20

Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 20
Study: 36110981

Group type: EXPERIMENTAL
Intervention: Sports dance exercises for 20-30 minutes, once a day initially, then twice a day for 180 days of continuous rehabilitation and exercise therapy.
Number of subjects: 81

Group type: COMPARATOR
Intervention: Routine rehabilitation nursing intervention including dietary nursing intervention and neck traction 3 times a week.
Number of subjects: 81
Study: 35056348

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection of prostatic utricle (PU)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Combined cystoscopy and laparoscopy for PU resection
Number of subjects: 1
Study: 34333138

Group type: EXPERIMENTAL
Intervention: Trust-based intervention at intervention sites promoting relationships between physician-investigators and minority-serving physicians and their minority patients.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CABANA trial intervention sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PACES trial intervention sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: STEADY‐PD III trial intervention sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMT CTN trial intervention sites
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control sites implementing only parent trials' recruitment procedures
Number of subjects: 0
Study: 32019847

Group type: EXPERIMENTAL
Intervention: Bright light (900 lx)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard light (90 lx)
Number of subjects: 27
Study: 33233594

Group type: EXPERIMENTAL
Intervention: Vitamin E with total carotenoids
Number of subjects: 1251
Study: 35659905

Group type: EXPERIMENTAL
Intervention: LACTIN-V (Lactobacillus crispatus CTV-05)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 33098255

Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Brain CT
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: NSE
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: S-100β
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: SSEP
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: EEG
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Brain stem reflex
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Motor response
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Myoclonus
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: GWR value < 1.1
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Status epilepticus
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Burst suppression
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: NSE and S-100 knowledge
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Timing of neurological prognostication
Number of subjects: 1600
Study: 32546129

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Suicide Prevention for psychosis (CBSPp) plus Treatment As Usual (TAU)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU) alone
Number of subjects: 250
Study: 34270810

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33212328

Group type: EXPERIMENTAL
Intervention: BuzzyⓇ device
Number of subjects: 219

Group type: COMPARATOR
Intervention: Lidocaine patch
Number of subjects: 219
Study: 35320164

Group type: EXPERIMENTAL
Intervention: Dynamic resistance group C
Number of subjects: 102

Group type: COMPARATOR
Intervention: Aerobic group A
Number of subjects: 102

Group type: COMPARATOR
Intervention: Resistance group B
Number of subjects: 102
Study: 32174343

Group type: EXPERIMENTAL
Intervention: Patient safety dashboard
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electronic health record
Number of subjects: 0
Study: 34995827

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Standard medical treatment (no-EVT)
Number of subjects: 171
Study: 33950535

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (BUP-NX)
Number of subjects: 283
Study: 33166482

Group type: EXPERIMENTAL
Intervention: Peer comparisons intervention group
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (individual feedback only)
Number of subjects: 88
Study: 35260342

Group type: EXPERIMENTAL
Intervention: Cetuximab (loading dose 400 mg/m2 day 1; subsequent weekly 250 mg/m2 doses until two weeks postradiotherapy) + Cisplatin (75 mg/m2) + Pemetrexed (500 mg/m2) + Radiotherapy (maximally 66 Gy starting on day 22)
Number of subjects: 106
Study: 33064597

Group type: EXPERIMENTAL
Intervention: Atrazine at concentrations of 2, 4, 8, 16, and 32 mg L‐1
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Atrazine at concentrations of 0.18, 6, 12, and 18 mg L‐1 after air exposition stress
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (without herbicide)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group with solubility adjuvant (acetone)
Number of subjects: 147
Study: 32338756

Group type: EXPERIMENTAL
Intervention: Vitamin supplements
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Red meat consumption more than twice a week for dinner
Number of subjects: 197
Study: 616858955

Group type: EXPERIMENTAL
Intervention: Breathing pattern with a postexhalation rest period
Number of subjects: 40

Group type: COMPARATOR
Intervention: Breathing pattern without a postexhalation rest period
Number of subjects: 40
Study: 36332676

Group type: EXPERIMENTAL
Intervention: Self-management intervention delivered by mobile application (APP), 5 sessions at weeks 2, 4, 6, 8, and 12 after discharge
Number of subjects: 98

Group type: COMPARATOR
Intervention: Routine telephone counselling provided by follow-up nurses at the 12th week after discharge
Number of subjects: 98
Study: 34330854

Group type: EXPERIMENTAL
Intervention: Hands-Up program (combined exercise and education)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual physical therapy (control)
Number of subjects: 74
Study: 32580724

Group type: EXPERIMENTAL
Intervention: Immediate sleep diagnostics and intervention (TAU+SI-T0)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed start of sleep intervention (TAU+SI-T1; 6 months after inclusion)
Number of subjects: 0
Study: 36064612

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 33259976

Group type: EXPERIMENTAL
Intervention: Lidocaine throat spray
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nebulized lidocaine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lidocaine throat spray and nebulized lidocaine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 33171589

Group type: EXPERIMENTAL
Intervention: Cod Protein Hydrolysate (CPH) 4 g protein
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0 g protein)
Number of subjects: 30
Study: 35322077

Group type: EXPERIMENTAL
Intervention: favipiravir
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Number of subjects: 150

Group type: COMPARATOR
Intervention: standard care
Number of subjects: 150
Study: 32890650

Group type: EXPERIMENTAL
Intervention: Carotid revascularization within 3 months after diagnosis
Number of subjects: 795512

Group type: EXPERIMENTAL
Intervention: Carotid revascularization rates over time
Number of subjects: 795512

Group type: EXPERIMENTAL
Intervention: Physician-specific carotid revascularization rates
Number of subjects: 795512

Group type: EXPERIMENTAL
Intervention: Physician characteristics associated with higher revascularization rates
Number of subjects: 795512

Group type: EXPERIMENTAL
Intervention: Comparison of surgeon types
Number of subjects: 795512
Study: 35138634

Group type: EXPERIMENTAL
Intervention: AuraGain™
Number of subjects: 100

Group type: COMPARATOR
Intervention: i-gel™
Number of subjects: 100
Study: 32519066

Group type: EXPERIMENTAL
Intervention: Novel biotechnology-based strategies to reduce LDL-C, non-HDL-C, triglyceride, apolipoprotein B, and Lp(a) levels.
Number of subjects: 0
Study: 35775451

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists (GLP-1RAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 34432829

Group type: EXPERIMENTAL
Intervention: Presentation at ≥16 weeks GA
Number of subjects: 10231

Group type: EXPERIMENTAL
Intervention: Presentation at ≥24 weeks GA
Number of subjects: 10231

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 10231

Group type: EXPERIMENTAL
Intervention: Higher parity (1-4 births)
Number of subjects: 10231

Group type: EXPERIMENTAL
Intervention: Higher parity (five or more births)
Number of subjects: 10231

Group type: EXPERIMENTAL
Intervention: Lower educational attainment (primary)
Number of subjects: 10231

Group type: EXPERIMENTAL
Intervention: Lower educational attainment (secondary)
Number of subjects: 10231

Group type: EXPERIMENTAL
Intervention: Lower educational attainment (university)
Number of subjects: 10231

Group type: EXPERIMENTAL
Intervention: Contributing to household income
Number of subjects: 10231

Group type: EXPERIMENTAL
Intervention: History of spontaneous abortion
Number of subjects: 10231

Group type: EXPERIMENTAL
Intervention: Pregnancy testing
Number of subjects: 10231

Group type: EXPERIMENTAL
Intervention: Residing in the same district as the health facility
Number of subjects: 10231

Group type: EXPERIMENTAL
Intervention: Residing in the same catchment area as the health facility
Number of subjects: 10231

Group type: EXPERIMENTAL
Intervention: Prior preterm delivery
Number of subjects: 10231

Group type: EXPERIMENTAL
Intervention: Prior low birthweight delivery
Number of subjects: 10231

Group type: EXPERIMENTAL
Intervention: No obstetric history
Number of subjects: 10231
Study: 33201033

Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI)
Number of subjects: 4760

Group type: COMPARATOR
Intervention: No Traumatic Brain Injury (Control)
Number of subjects: 4760

Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI) in men aged 60 to 70
Number of subjects: 4760

Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI) in men aged 71 to 80
Number of subjects: 4760

Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI) in women aged 81 to 90
Number of subjects: 4760
Study: 36484664

Group type: EXPERIMENTAL
Intervention: Osteotome technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional drilling (control group)
Number of subjects: 30
Study: 33727656

Group type: EXPERIMENTAL
Intervention: Risk populations (CK, LIA, CIR, LT)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Blood donors (BD)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Total sample
Number of subjects: 400
Study: 35017305

Group type: EXPERIMENTAL
Intervention: TNK 0.25 mg/kg
Number of subjects: 137

Group type: COMPARATOR
Intervention: TNK 0.40 mg/kg
Number of subjects: 137

Group type: COMPARATOR
Intervention: Alteplase 0.90 mg/kg
Number of subjects: 137
Study: 34391509

Group type: EXPERIMENTAL
Intervention: Stockholm3 score of 0.11 or higher
Number of subjects: 2293

Group type: COMPARATOR
Intervention: PSA of 3 ng/mL or higher
Number of subjects: 2293

Group type: EXPERIMENTAL
Intervention: Stockholm3 score of 0.11 or higher combined with MRI-targeted and systematic biopsies
Number of subjects: 2293

Group type: EXPERIMENTAL
Intervention: Stockholm3 score of 0.15 or higher
Number of subjects: 2293
Study: 35771361

Group type: EXPERIMENTAL
Intervention: 40 mg citalopram
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 8 mg reboxetine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33687926

Group type: EXPERIMENTAL
Intervention: Early ACL reconstruction
Number of subjects: 167

Group type: COMPARATOR
Intervention: Rehabilitation followed by optional delayed ACL reconstruction
Number of subjects: 167
Study: 35739299

Group type: EXPERIMENTAL
Intervention: VOR/HCQ
Number of subjects: 42

Group type: COMPARATOR
Intervention: RGF
Number of subjects: 42
Study: 33818933

Group type: EXPERIMENTAL
Intervention: Adenoprosin (once a day for three months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alpha-blockers and fluoroquinolones (control group)
Number of subjects: 60
Study: 35675032

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg/kg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Rocuronium 0.3 mg/kg
Number of subjects: 34
Study: 36296952

Group type: EXPERIMENTAL
Intervention: Fruits and vegetables containing phenylalanine 76−100 mg/100 g, additional intake of 50 mg/day and then 100 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Milk protein sources, additional intake of 50 mg/day and then 100 mg/day
Number of subjects: 16
Study: 32293929

Group type: EXPERIMENTAL
Intervention: Three-level cluster-randomized design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R package PowerUpR and its Shiny application
Number of subjects: 0